Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
PLX Protalix BioTherapeutics Inc
- Stocks
- Healthcare
- NYSEAMERICAN: PLX
Price (delayed)
$1.655
Market cap
$131.75M
P/E Ratio
33.1
Dividend/share
N/A
EPS
$0.05
Enterprise value
$117.53M
Protalix is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx®. Protalix was the first company to
Highlights
PLX's debt has plunged by 80% YoY and by 5% from the previous quarter
Protalix BioTherapeutics's quick ratio has surged by 71% YoY and by 10% QoQ
PLX's EPS has dropped by 50% year-on-year but it is up by 25% since the previous quarter
PLX's net income is down by 43% year-on-year but it is up by 33% since the previous quarter
Protalix BioTherapeutics's gross margin has decreased by 20% YoY and by 8% QoQ
Key stats
What are the main financial stats of PLX
Market
Valuations
Earnings
Shares outstanding
79.61M
Market cap
$131.75M
Enterprise value
$117.53M
Price to earnings (P/E)
33.1
Price to book (P/B)
2.86
Price to sales (P/S)
2.12
EV/EBIT
20.15
EV/EBITDA
16.41
EV/Sales
1.97
Revenue
$59.76M
Gross profit
$29.87M
Operating income
$4.63M
Net income
$3.91M
EBIT
$5.83M
EBITDA
$7.16M
Free cash flow
-$1.56M
Per share
Balance sheet
Liquidity
EPS
$0.05
EPS diluted
$0.04
Free cash flow per share
-$0.02
Book value per share
$0.58
Revenue per share
$0.78
TBVPS
$0.96
Total assets
$73.89M
Total liabilities
$28.68M
Debt
$5.24M
Equity
$45.21M
Working capital
$36.19M
Debt to equity
0.12
Current ratio
2.49
Quick ratio
1.62
Net debt/EBITDA
-1.99
Margins
Efficiency
Dividend
EBITDA margin
12%
Gross margin
50%
Net margin
6.5%
Operating margin
7.7%
Return on assets
5.2%
Return on equity
10.5%
Return on invested capital
19.3%
Return on capital employed
11.8%
Return on sales
9.8%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
PLX stock price
How has the Protalix BioTherapeutics stock price performed over time
Intraday
-0.3%
1 week
-41.73%
1 month
-36.83%
1 year
42.67%
YTD
-11.97%
QTD
-35.35%
Financial performance
How have Protalix BioTherapeutics's revenue and profit performed over time
Revenue
$59.76M
Gross profit
$29.87M
Operating income
$4.63M
Net income
$3.91M
Gross margin
50%
Net margin
6.5%
The operating margin has decreased by 43% YoY but it has increased by 5% from the previous quarter
PLX's net income is down by 43% year-on-year but it is up by 33% since the previous quarter
Protalix BioTherapeutics's operating income has decreased by 43% YoY but it has increased by 18% QoQ
PLX's net margin is down by 43% YoY but it is up by 18% from the previous quarter
Price vs fundamentals
How does PLX's price correlate with its fundamentals
Growth
What is Protalix BioTherapeutics's growth rate over time
Valuation
What is Protalix BioTherapeutics stock price valuation
P/E
33.1
P/B
2.86
P/S
2.12
EV/EBIT
20.15
EV/EBITDA
16.41
EV/Sales
1.97
PLX's EPS has dropped by 50% year-on-year but it is up by 25% since the previous quarter
Protalix BioTherapeutics's equity has surged by 52% YoY and by 4.6% QoQ
PLX's P/B is 10% below its last 4 quarters average of 3.2
PLX's price to sales (P/S) is 12% higher than its 5-year quarterly average of 1.9 but 11% lower than its last 4 quarters average of 2.4
Protalix BioTherapeutics's revenue has increased by 12% from the previous quarter
Efficiency
How efficient is Protalix BioTherapeutics business performance
Protalix BioTherapeutics's return on equity has decreased by 46% YoY but it has increased by 19% QoQ
The ROA has grown by 41% from the previous quarter but it has contracted by 33% YoY
PLX's return on sales is down by 40% year-on-year
The return on invested capital has declined by 16% year-on-year but it has increased by 11% since the previous quarter
Dividends
What is PLX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for PLX.
Financial health
How did Protalix BioTherapeutics financials performed over time
PLX's total assets is 158% greater than its total liabilities
The company's current ratio has surged by 80% YoY and by 6% QoQ
Protalix BioTherapeutics's quick ratio has surged by 71% YoY and by 10% QoQ
PLX's debt is 88% less than its equity
The debt to equity has dropped by 87% year-on-year and by 8% since the previous quarter
PLX's debt has plunged by 80% YoY and by 5% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.